Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 5 min ago
Peer-reviewedCC BYArthritis Care and Research

Oral glucocorticoids added to ILD‐modifying therapy in systemic sclerosis‐associated interstitial lung disease: a target trial emulation study from the EUSTAR database.

2 more authors

Abstract

OBJECTIVES: We aimed to estimate whether adding oral glucocorticoids to ILD-modifying therapy improves 12-month lung outcomes in systemic sclerosis-associated interstitial lung disease (SSc-ILD). METHODS: We emulated a target trial using the EUSTAR database. Eligible adults with confirmed SSc-ILD initiated an eligible ILD-modifying therapy at baseline (T0), either alone or with oral glucocorticoids added (prednisone-equivalent dose ≤20 mg/day). Follow-up ended at the visit closest to 12 months within a 9 to 15-month window. The primary outcome was the between-group difference in change in FVC (% predicted). Secondary outcomes were progressive lung fibrosis and isolated DLCO decline ≥15%. We used multiple imputation (m=80), stabilised inverse probability of treatment weighting, robust variance estimators and Rubin's rules. RESULTS: Of 443 patients, 185 (41.8%) received oral glucocorticoids with ILD-modifying therapy and 258 (58.2%) received ILD-modifying therapy alone. Adding oral glucocorticoids was not associated with improved 12-month FVC. The adjusted mean difference in FVC change was -2.10 percentage points (95% CI -4.68 to 0.47; p=0.11). There was no clear difference in progressive lung fibrosis (RR 1.40, 95% CI 0.83 to 2.35) or isolated DLCO decline ≥15% (RR 0.81, 95% CI 0.39 to 1.69). Findings were consistent in the truncated-weight sensitivity analysis. CONCLUSION: Adding oral glucocorticoids to ILD-modifying therapy was not associated with improved 12-month FVC in SSc-ILD. Secondary outcomes were sparse and should be interpreted cautiously.

Related

  1. Prognostic role of nailfold videocapillaroscopy in predicting progression in systemic sclerosis-associated interstitial lung disease: a systematic review and narrative synthesis
    Milan Bogojevic, Rifat Medjedovic, Milica Markovic +3
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyFrontiersCrossref
  2. Potential adjunct disease-modifying effects of exercise and physical activity in multiple sclerosis: an umbrella review of disease activity/progression, safety, and inflammatory-neurobiomarker evidence
    Jianmin Dai, Weibao Liang, Yufeng Kang +4
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyFrontiersCrossref
  3. SEZ6L2 antibody-associated cerebellar ataxia mimicking alcohol-related brain damage - diagnostic challenges and successful treatment with double filtration plasmapheresis and glucocorticoids: a case report
    Chunping Zhu, Tiantian Jiang, Bin Liu +2
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyFrontiersCrossref
  4. Unilateral MR-guided laser interstitial thermal therapy thalamotomy for refractory multiple sclerosis tremor: 12-month outcomes in four patients
    Mickael Aubignat, Mélissa Tir, Martial Ouendo +5
    Multiple Sclerosis and Related DisordersPeer-reviewedCC BYFull textNeuroscienceHAL
  5. Correlative and Live-Cell Imaging of S100B-Promoter-Associated Interstitial Cells from the Cardiac Sinoatrial Node and Valves
    Dmitry B. Zorov, Miguel Calvo-Rubio, Robert E. Monticone +10
    CellsPeer-reviewedCC BYFull textCell biologyEurope PMC
BibTeX
@article{salis2026oral,
  title = {{Oral glucocorticoids added to ILD‐modifying therapy in systemic sclerosis‐associated interstitial lung disease: a target trial emulation study from the EUSTAR database.}},
  author = {Zubeyir Salis and Simona Truglia and Oliver Distler and Gábor Kumánovics and Gianluca Moroncini and David Launay and Silvia Bellando-Randone and Gonçalo Boleto and Nicoletta del Papa and Ana Maria Gheorghiu and Duygu Temiz Karadag and Zguro Batalov and Gabriella Szucs and Michele Iudici},
  journal = {Arthritis Care and Research},
  year = {2026},
  month = nov,
  doi = {10.1002/acr.80205},
  url = {https://hal.science/hal-05864436v1},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Oral glucocorticoids added to ILD‐modifying therapy in systemic sclerosis‐associated interstitial lung disease: a target trial emulation study from the EUSTAR database.
AU  - Zubeyir Salis
AU  - Simona Truglia
AU  - Oliver Distler
AU  - Gábor Kumánovics
AU  - Gianluca Moroncini
AU  - David Launay
AU  - Silvia Bellando-Randone
AU  - Gonçalo Boleto
AU  - Nicoletta del Papa
AU  - Ana Maria Gheorghiu
AU  - Duygu Temiz Karadag
AU  - Zguro Batalov
AU  - Gabriella Szucs
AU  - Michele Iudici
PY  - 2026
DA  - 2026/11/11
JO  - Arthritis Care and Research
DO  - 10.1002/acr.80205
UR  - https://hal.science/hal-05864436v1
AB  - OBJECTIVES: We aimed to estimate whether adding oral glucocorticoids to ILD-modifying therapy improves 12-month lung outcomes in systemic sclerosis-associated interstitial lung disease (SSc-ILD). METHODS: We emulated a target trial using the EUSTAR database. Eligible adults with confirmed SSc-ILD initiated an eligible ILD-modifying therapy at baseline (T0), either alone or with oral glucocorticoids added (prednisone-equivalent dose ≤20 mg/day). Follow-up ended at the visit closest to 12 months within a 9 to 15-month window. The primary outcome was the between-group difference in change in FVC (% predicted). Secondary outcomes were progressive lung fibrosis and isolated DLCO decline ≥15%. We used multiple imputation (m=80), stabilised inverse probability of treatment weighting, robust variance estimators and Rubin's rules. RESULTS: Of 443 patients, 185 (41.8%) received oral glucocorticoids with ILD-modifying therapy and 258 (58.2%) received ILD-modifying therapy alone. Adding oral glucocorticoids was not associated with improved 12-month FVC. The adjusted mean difference in FVC change was -2.10 percentage points (95% CI -4.68 to 0.47; p=0.11). There was no clear difference in progressive lung fibrosis (RR 1.40, 95% CI 0.83 to 2.35) or isolated DLCO decline ≥15% (RR 0.81, 95% CI 0.39 to 1.69). Findings were consistent in the truncated-weight sensitivity analysis. CONCLUSION: Adding oral glucocorticoids to ILD-modifying therapy was not associated with improved 12-month FVC in SSc-ILD. Secondary outcomes were sparse and should be interpreted cautiously.
SN  - 2151-464X
SN  - 2151-4658
ER  -